Premium
Challenges in Drug Development Posed by the COVID‐19 Pandemic: An Opportunity for Clinical Pharmacology
Author(s) -
Venkatakrishnan Karthik,
Yalkinoglu Oezkan,
Dong Jennifer Q.,
Benincosa Lisa J.
Publication year - 2020
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1879
Subject(s) - pandemic , drug development , covid-19 , mindset , clinical trial , clinical pharmacology , medicine , drug , intensive care medicine , pharmacology , disease , infectious disease (medical specialty) , virology , computer science , outbreak , artificial intelligence
The unprecedented challenges posed by the coronavirus disease 2019 (COVID‐19) pandemic highlight the urgency for applying clinical pharmacology and model‐informed drug development in (i) dosage optimization for COVID‐19 therapies, (ii) approaching therapeutic dilemmas in clinical trial settings, and (iii) maximizing value of information from impacted non–COVID‐19 trials. More than ever, we have a responsibility for adaptive evidence synthesis with a Totality of Evidence mindset in this race against time across biomedical research, clinical practice, drug development, and regulation.